Podcast Episodes
Back to SearchFloaters: Imaging Tools, Decision-Making, Including Surgery and Patient Counseling
Episode 534
Drs. Dedania and Modi discuss vitreous opacities, or floaters, including imaging, evaluating, and when and whether to pursue surgery. They discuss co…
1 year, 1 month ago
Geographic Atrophy: Navigating the Latest Advances in Care
Episode 533
Drs. Modi and Dedania discuss imaging, biomarkers, and diagnosis in geographic atrophy, as well as current therapies and those in late stage clinical…
1 year, 1 month ago
“What does full FDA approval of Moderna’s COVID vaccine mean for high-risk kids under 12?”
Episode 532
This podcast highlights three updates: Moderna’s Spikevax COVID-19 vaccine is now fully FDA-approved for high-risk children 6 months to 11 years, tho…
1 year, 1 month ago
Maintenance Therapy Strategies in Small Cell Lung Cancer
Episode 531
Drs. Sabari and Socinski discuss maintenance therapy strategies in small cell lung cancer, including immunotherapy, chemotherapy, targeted agents, an…
1 year, 1 month ago
ASCO 2025: Emerging Therapies in Small Cell Lung Cancer
Episode 530
Drs. Socinski and Sabari discuss a couple of abstracts from ASCO 2025 about emerging therapeutics in small cell lung cancer.
1 year, 1 month ago
ASCO 2025: Updates in Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Episode 529
Mark A. Socinski, MD and Joshua Sabari, MD review new data from ASCO 2025 that have a substantial impact on how oncologists treat patients with exten…
1 year, 1 month ago
How many avoidable deaths could occur by 2030 if abrupt funding cuts to USAID are not reversed?
Episode 528
A Lancet analysis warns that USAID cuts could cause over 14 million preventable deaths by 2030, reversing decades of progress against infectious dise…
1 year, 1 month ago
What’s the latest on the national outbreak of Measles in the US?
Episode 527
The measles outbreak stands at 1,227 confirmed cases in 2025 so far—nearly five times the total for all of 2024—mostly among unvaccinated individuals…
1 year, 1 month ago
ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast06, SHR-A1811, Rechallenge With T-DXd Post Grade 1 ILD, and More
Episode 526
Drs. Yuan and Callahan discuss data presented at ASCO 2025 about DESTINY-Breast06, SHR-A1811, and TQB2101, along with real-world data on rechallengin…
1 year, 1 month ago
ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast09, PATINA, MINI Trial, and More
Episode 525
Drs. Callahan and Yuan discuss data presented at ASCO 2025 on DESTINY-Breast09, PATINA, and MINI Trial, the utility of PFS-2 as an endpoint, and sequ…
1 year, 1 month ago